INMODE LTD (INMD) Stock Fundamental Analysis
USA - NASDAQ:INMD - IL0011595993 - Common Stock
14.93 USD
-0.03 (-0.2%)
14.93 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to INMD. INMD was compared to 191 industry peers in the Health Care Equipment & Supplies industry. INMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. INMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make INMD a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year INMD was profitable.
In the past year INMD had a positive cash flow from operations.
Each year in the past 5 years INMD has been profitable.
In the past 5 years INMD always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of INMD (25.23%) is better than 98.43% of its industry peers.
INMD has a Return On Equity of 28.44%. This is amongst the best in the industry. INMD outperforms 97.91% of its industry peers.
The Return On Invested Capital of INMD (16.27%) is better than 96.34% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INMD is significantly above the industry average of 8.46%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(16.27%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.23% | ||
| ROE | 28.44% | ||
| ROIC | 16.27% |
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
1.3 Margins
INMD has a Profit Margin of 44.50%. This is amongst the best in the industry. INMD outperforms 97.91% of its industry peers.
INMD's Profit Margin has improved in the last couple of years.
INMD has a better Operating Margin (28.54%) than 95.29% of its industry peers.
In the last couple of years the Operating Margin of INMD has declined.
With an excellent Gross Margin value of 79.98%, INMD belongs to the best of the industry, outperforming 92.67% of the companies in the same industry.
In the last couple of years the Gross Margin of INMD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.54% | ||
| PM (TTM) | 44.5% | ||
| GM | 79.98% |
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INMD is creating value.
Compared to 1 year ago, INMD has less shares outstanding
The number of shares outstanding for INMD has been increased compared to 5 years ago.
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.84
WACC8.82%
2.3 Liquidity
A Current Ratio of 9.60 indicates that INMD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.60, INMD belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
INMD has a Quick Ratio of 8.58. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.58, INMD belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.6 | ||
| Quick Ratio | 8.58 |
3. Growth
3.1 Past
INMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.04%.
Measured over the past years, INMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.97% on average per year.
INMD shows a decrease in Revenue. In the last year, the revenue decreased by -3.61%.
The Revenue has been growing by 20.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
3.2 Future
Based on estimates for the next years, INMD will show a small growth in Earnings Per Share. The EPS will grow by 1.43% on average per year.
INMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.74% yearly.
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.43%
EPS Next 5YN/A
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
INMD is valuated cheaply with a Price/Earnings ratio of 7.86.
Based on the Price/Earnings ratio, INMD is valued cheaper than 95.81% of the companies in the same industry.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.20.
INMD is valuated reasonably with a Price/Forward Earnings ratio of 8.68.
94.76% of the companies in the same industry are more expensive than INMD, based on the Price/Forward Earnings ratio.
INMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.86 | ||
| Fwd PE | 8.68 |
4.2 Price Multiples
99.48% of the companies in the same industry are more expensive than INMD, based on the Enterprise Value to EBITDA ratio.
97.38% of the companies in the same industry are more expensive than INMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.07 | ||
| EV/EBITDA | 2.16 |
4.3 Compensation for Growth
The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.34
EPS Next 2Y-1.69%
EPS Next 3Y1.43%
5. Dividend
5.1 Amount
No dividends for INMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.93
-0.03 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners70.51%
Inst Owner Change-14.05%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap943.73M
Analysts72.31
Price Target16.58 (11.05%)
Short Float %6.45%
Short Ratio3.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.54%
Min EPS beat(2)-13.69%
Max EPS beat(2)10.61%
EPS beat(4)2
Avg EPS beat(4)-3.62%
Min EPS beat(4)-20.27%
Max EPS beat(4)10.61%
EPS beat(8)3
Avg EPS beat(8)-6.64%
EPS beat(12)7
Avg EPS beat(12)-0.75%
EPS beat(16)11
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-2.62%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-9.96%
Max Revenue beat(4)0.53%
Revenue beat(8)1
Avg Revenue beat(8)-7%
Revenue beat(12)5
Avg Revenue beat(12)-3.84%
Revenue beat(16)9
Avg Revenue beat(16)-1.49%
PT rev (1m)0%
PT rev (3m)-5.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.37%
EPS NY rev (1m)-6.87%
EPS NY rev (3m)-6.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.51%
Revenue NY rev (1m)-3.24%
Revenue NY rev (3m)-4.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.86 | ||
| Fwd PE | 8.68 | ||
| P/S | 2.35 | ||
| P/FCF | 9.07 | ||
| P/OCF | 9.02 | ||
| P/B | 1.5 | ||
| P/tB | 1.5 | ||
| EV/EBITDA | 2.16 |
EPS(TTM)1.9
EY12.73%
EPS(NY)1.72
Fwd EY11.52%
FCF(TTM)1.65
FCFY11.02%
OCF(TTM)1.65
OCFY11.08%
SpS6.35
BVpS9.94
TBVpS9.94
PEG (NY)N/A
PEG (5Y)0.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.23% | ||
| ROE | 28.44% | ||
| ROCE | 17.86% | ||
| ROIC | 16.27% | ||
| ROICexc | 79.63% | ||
| ROICexgc | 79.63% | ||
| OM | 28.54% | ||
| PM (TTM) | 44.5% | ||
| GM | 79.98% | ||
| FCFM | 25.9% |
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score7
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 81.89% | ||
| Cap/Sales | 0.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.67% | ||
| Profit Quality | 58.19% | ||
| Current Ratio | 9.6 | ||
| Quick Ratio | 8.58 | ||
| Altman-Z | N/A |
F-Score7
WACC8.82%
ROIC/WACC1.84
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.43%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A
EBIT growth 1Y-14.49%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-39.83%
EBIT Next 3Y-11.16%
EBIT Next 5YN/A
FCF growth 1Y-40.81%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-40.87%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%